NASDAQ · MNPR
Monopar Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MNPR: Nov 12, 2026
Monopar Therapeutics Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.86. The reported EPS for the same quarter last year was $-0.48.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.86 | $-0.62 | $-1.28 | 5 |
| Dec 2026 | $-1.13 | $-0.43 | $-2.61 | 5 |
| Mar 2027 | $-0.76 | $-0.01 | $-1.52 | 3 |
| Jun 2027 | $-0.82 | $-0.17 | $-1.30 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Zacks- BNK Invest · Aug 20, 9:04 AM EDTMNPR Crosses Above Average Analyst TargetIn recent trading, shares of Monopar Therapeutics Inc (Symbol: MNPR) have crossed above the average analyst 12-month target price of $120.23, changing hands for $123.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgr
- RTTNews · Aug 19, 8:41 AM EDTMNPR Names New Medical Affairs Head As ALXN1840 Advances Toward FDA Decision(RTTNews) – Monopar Therapeutics Inc. (MNPR) appointed Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President and Head of Medical Affairs, effective September 1, 2026, as the company prepares for potential U.S. FDA approval of ALXN1840 for Wilson disease.
- RTTNews · Aug 12, 10:33 AM EDTMonopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway(RTTNews) – Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss, and provided an update on its investigational pipeline.
- RTTNews · Aug 7, 6:30 AM EDTBiotech Stocks At 52-Week Highs – DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX(RTTNews) – The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.
- RTTNews · Jul 21, 3:41 AM EDTBiotech Stocks At 52-Week Highs – XNCR, COAG, MNPR, SOPH, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies.
- RTTNews · Jul 10, 8:17 AM EDTBiotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT(RTTNews) – The following biotech companies climbed to 52-week highs on July 9, 2026, driven by key catalysts like encouraging regulatory updates and clinical trial milestones.
- RTTNews · Jun 30, 11:07 AM EDTMonopar's ALXN1840 Gets FDA's Rare Pediatric Disease Designation For Wilson Disease(RTTNews) – Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to ALXN1840 for the treatment of Wilson disease.
- RTTNews · Jun 30, 8:35 AM EDTMonopar Therapeutics Granted Rare Pediatric Disease Designation To ALXN1840 To Treat Wilson Disease(RTTNews) – Biopharmaceutical company Monopar Therapeutics, Inc. (MNPR) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company's late-stage candidate for the trea
- RTTNews · Jun 23, 11:13 PM EDTTop Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment(RTTNews) – Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and Galectin Therapeutics, which has reached
- Zacks · Jun 15, 9:55 AM EDTWall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to TradeThe mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- RTTNews · May 22, 10:47 AM EDTWeekly Buzz: GH Wins FDA Nod; NMPA Green Lights HCM; MDT To Acquire SPR ; BIIB HALTS BIIB112(RTTNews) – This week's biotech landscape saw regulatory approvals across the U.S., Canada, and China, alongside collaborations, acquisitions, program halts, and positive data readouts spanning multiple therapeutic areas, including severely calcified coronary artery disease, Wils
- RTTNews · May 20, 4:38 AM EDTMonopar's ALXN1840 Shows Significant Copper Reduction In Phase 2 Trial For Wilson Disease(RTTNews) – Monopar Therapeutics Inc. (MNPR), on Monday announced that Hepatology Communications has published a peer-reviewed manuscript entitled "Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial." reporting Phase 2 r
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Monopar Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.